Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Thomas Cheung Yau , Vikki Tang , Jess Chan , Gin Wai Kwok , Joanne Chiu , Roland Ching-Yu Leung , Bryan Li , Tan To Cheung
Background: The outcomes of tyrosine kinase inhibitor(TKI) treatment after immune checkpoint inhibitors (PD-1i, PD-L1i, CTLA-4i) in unresectable/advanced HCC population is largely unknown. Methods: Retrospective analysis of advanced HCC patients treated with immune checkpoint inhibitors followed by TKI therapy at Queen Mary Hospital, Hong Kong were reviewed for the outcomes. Patients received locoregional therapy immediately after immunotherapy were excluded. Results: From January 2016 to July 2018, 30 HCC patients (83% of HBV, 80% of Child Pugh A, 83% of EHS/ MVI, median AFP=1,353ng/mL) who received TKI (11 lenvatinib, 10 sorafenib, 6 regorafenib, 3 axitinib) after immunotherapy were identified. TKI post-immunotherapy ("index TKI") was administered as third-line or beyond in 70% of patients. At the time of analysis (September 2018), median duration of index TKI was 72 days (IQR 36-119∗) (∗3 patients were still receiving TKI). AFP declined in 53% of patients and the median change from baseline to nadir was -25% (IQR -65% to +6%). 40% of patients received subsequent systemic therapy. Median OS from index TKI was 602 days (95%CI 124-not reached; death event rate: 47%). 3 patients achieved partial response to TKI and they had at least stable disease with the previous immunotherapy. No unexpected safety issues of TKI and death related to adverse events were noted (table). Conclusions: TKI is active with good tolerabilty following immunotherapy in advanced HCC patients.
G1 | G2 | G3 | G4 | |
---|---|---|---|---|
General | ||||
Hypertension | 7% | 33% | 7% | 0% |
HFSR | 13% | 23% | 3% | - |
Malaise | 30% | 7% | - | - |
Diarrhea | 10% | 17% | 7% | 0% |
Rash, unspecified | 23% | 0% | 3% | 0% |
Nausea | 20% | 0% | 3% | - |
Hyponatremia | 3% | - | 17% | 0% |
Anorexia | 13% | 7% | 0% | 0% |
Bleeding | 0% | 10% | 0% | 0% |
Hypothyroidism | 0% | 7% | 0% | 0% |
Oral mucositis | 0% | 7% | 0% | 0% |
Vomiting | 7% | 0% | 0% | 0% |
Weight loss | 7% | 0% | 0% | 0% |
Liver function | ||||
Hypoalbuminemia | 40% | 20% | 7% | 0% |
Hyperbilirubinemia | 23% | 13% | 13% | 3% |
ALT increased | 23% | 13% | 13% | 0% |
Hematological | ||||
Neutropenia | 10% | 10% | 13% | 0% |
Thrombocytopenia | 17% | 13% | 3% | 0% |
Anemia | 0% | 10% | 13% | 0% |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Linda Wu
2023 ASCO Annual Meeting
First Author: Jinpeng Li
2021 ASCO Annual Meeting
First Author: Thomas Yau
2022 ASCO Annual Meeting
First Author: Feng Xue